Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis regardless of causative micro-organism ISRCTN74215569

摘要

IntroductionPROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) was a phase III, randomized, double blind, placebo controlled, multicenter trial conducted in patients with severe sepsis from 164 medical centers. Here we report data collected at study entry for 1690 patients and over the following 7 days for the 840 patients who received placebo (in addition to usual standard of care).